Skip to main content
. 2015 Oct 21;7(4):2094–2109. doi: 10.3390/cancers7040879

Figure 3.

Figure 3

Survival based on tumor subsite, EGFR amplification status. Five-year overall survival (x-axis in months) from 522 TCGA patients with CNV data on EGFR amplification in oral cavity (OC) and laryngeal (L) SCCs. A trend to worse overall survival based on EGFR amplification is seen with laryngeal SCCs (log-rank p = 0.08), but not oral cavity SCCs (log-rank p = 0.263).